Fagron NV - Asset Resilience Ratio
Fagron NV (FAGR) has an Asset Resilience Ratio of 0.01% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Fagron NV (FAGR) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Fagron NV's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Fagron NV total assets.
Liquid Assets Composition Over Time
This chart breaks down Fagron NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore FAGR long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €93.00K | 0.01% |
| Total Liquid Assets | €93.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Fagron NV maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Fagron NV Industry Peers by Asset Resilience Ratio
Compare Fagron NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Fagron NV (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Fagron NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | €11.00K ≈ $12.86K |
€1.24 Billion ≈ $1.45 Billion |
-0.08pp |
| 2024-12-31 | 0.08% | €886.00K ≈ $1.04 Million |
€1.08 Billion ≈ $1.27 Billion |
-0.34pp |
| 2023-12-31 | 0.42% | €4.27 Million ≈ $4.99 Million |
€1.01 Billion ≈ $1.18 Billion |
+0.38pp |
| 2022-12-31 | 0.05% | €451.00K ≈ $527.27K |
€971.01 Million ≈ $1.14 Billion |
+0.21pp |
| 2021-12-31 | -0.16% | €-1.32 Million ≈ $-1.54 Million |
€800.42 Million ≈ $935.78 Million |
-0.05pp |
| 2020-12-31 | -0.11% | €-862.00K ≈ $-1.01 Million |
€752.83 Million ≈ $880.13 Million |
+0.14pp |
| 2019-12-31 | -0.26% | €-2.07 Million ≈ $-2.42 Million |
€801.24 Million ≈ $936.73 Million |
-0.45pp |
| 2018-12-31 | 0.19% | €1.29 Million ≈ $1.51 Million |
€682.77 Million ≈ $798.23 Million |
+0.22pp |
| 2017-12-31 | -0.03% | €-163.00K ≈ $-190.56K |
€594.05 Million ≈ $694.50 Million |
-0.12pp |
| 2016-12-31 | 0.09% | €816.00K ≈ $953.99K |
€868.05 Million ≈ $1.01 Billion |
+0.72pp |
| 2015-12-31 | -0.63% | €-4.32 Million ≈ $-5.05 Million |
€689.38 Million ≈ $805.96 Million |
-- |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more